Case report of neuromyelitis optica spectrum disorder: anti-MOG associated myelitis

April 14, 2023
1094
Specialities :
Resume

The article is devoted to the case report of a rare disease — neuromyelitis optica spectrum disorder, namely, anti-MOG associated myelitis. A brief literature review of information on neuroopticomyelitis spectrum diseases is given, the difference between the clinical forms is highlighted, and modern diagnostic criteria are given. A detailed description of the clinical case is presented, the process of diagnostic search is described, as well as the results of additional examination, on the basis of which the diagnosis is established.

References

  • 1. Devic E. (1894) Myélite subaiguë compliquée de névrite optique. Bull. Med., 8: 1033–1034.
  • 2. Gault F. (1894) De la neuromyélite optique aiguë. Thèse. In: Lyon, A. Rey.
  • 3. Modi G., Mochan A., Modi M., Saffer D. (2001) Demyelinating disorder of the central nervous system occurring in black South Africans. J. Neurol. Neurosurg. Psychiatr., 70(4): 500–505.
  • 4. Lennon V.A., Wingerchuk D.M., Kryzer T.J. et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, 364(9451): 2106–2112.
  • 5. Lennon V.A., Kryzer T.J., Pittock S.J. et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Еxperiment. Med., 202(4): 473–477.
  • 6. Saadoun S., Waters P., Bell B.A. et al. (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain, 133(2): 349–361.
  • 7. Papadopoulos M.C., Verkman A. (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol., 11(6): 535–544.
  • 8. Ratelade J., Zhang H., Saadoun S. et al. (2012) Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol., 123: 861–872.
  • 9. Reindl M., Jarius S., Rostasy K., Berger T. (2017) Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr. Opin. Neurol., 30(3): 295–301.
  • 10. Zamvil S.S., Slavin A.J. (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol. Neuroimmunol. Neuroinflamm., 2(1): e62.
  • 11. Melamed E., Levy M., Waters P.J. et al. (2015) Update on biomarkers in neuromyelitis optica. Neurol. Neuroimmunol. Neuroinflamm., 2(4).
  • 12. Quarles R.H. (2002) Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell. Mol. Life Sci. CMLS, 59: 1851–1871.
  • 13. Sharpe A.H., Freeman G.J. (2002) The B7–CD28 superfamily. Nat. Rev. Immunol., 2(2): 116–126.
  • 14. Marignier R., Hacohen Y., Cobo-Calvo A. et al. (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol., 20(9): 762–772.
  • 15. Uhlén M., Fagerberg L., Hallström B.M. et al. (2015) Tissue-based map of the human proteome. Science, 347(6220): 1260419.
  • 16. Corbali O., Chitnis T. (2023) Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front. Neurol., 14: 1137998.
  • 17. Takai Y., Misu T., Kaneko K. et al. (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain, 143(5): 1431–1446.
  • 18. Bradl M., Reindl M., Lassmann H. (2018) Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr. Opin. Neurol., 31(3): 325.
  • 19. Macrini C., Gerhards R., Winklmeier S. et al. (2021) Features of MOG required for recognition by patients with MOG antibody-associated disorders. Brain, 144(8): 2375–2389.
  • 20. Sabatino Jr.J.J., Pröbstel A.K., Zamvil S.S. (2019) B cells in autoimmune and neurodegenerative central nervous system diseases. Nature Rev. Neurosci., 20(12): 728–745.
  • 21. Wingerchuk D.M., Banwell B., Bennett J.L. et al. (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2): 177–189.
  • 22. Banwell B., Bennett J.L., Marignier R. et al. (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol., 22(3): 268–282.